Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

被引：0
|
作者：
William T. Cefalu
Kaj Stenlöf
Lawrence A. Leiter
John P. H. Wilding
Lawrence Blonde
David Polidori
John Xie
Daniel Sullivan
Keith Usiskin
William Canovatchel
Gary Meininger
机构：
[1] Louisiana State University,Pennington Biomedical Research Center
[2] Sahlgrenska University Hospital,Clinical Trial Center
[3] University of Toronto,Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St Michael’s Hospital, Division of Endocrinology and Metabolism
[4] University of Liverpool,Department of Obesity and Endocrinology
[5] Ochsner Medical Center,Department of Endocrinology, Diabetes, and Metabolic Diseases
[6] Janssen Research & Development,undefined
[7] LLC,undefined
[8] Janssen Research & Development,undefined
[9] LLC,undefined
来源：
Diabetologia | 2015年 / 58卷
关键词：
Body weight; Canagliflozin; Sodium glucose co-transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1183 / 1187
页数：4
相关论文
共 50 条
  • [1] Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
    Cefalu, William T.
    Stenlof, Kaj
    Leiter, Lawrence A.
    Wilding, John P. H.
    Blonde, Lawrence
    Polidori, David
    Xie, John
    Sullivan, Daniel
    Usiskin, Keith
    Canovatchel, William
    Meininger, Gary
    DIABETOLOGIA, 2015, 58 (06) : 1183 - 1187
  • [2] Audit to evaluate the effect of canagliflozin on HbA1c, blood pressure and weight in patients with Type 2 diabetes
    Yasin, Z.
    Darzy, K.
    DIABETIC MEDICINE, 2018, 35 : 89 - 89
  • [3] Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Merton, Katherine
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Inman, Doreen
    Meininger, Gary
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (02) : 313 - 318
  • [4] Achieving composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Merton, K.
    Davies, M. J.
    Vijapurkar, U.
    Inman, D.
    Meininger, G.
    DIABETOLOGIA, 2016, 59 : S345 - S345
  • [5] Canagliflozin provides reductions in HbA1c, body weight, and blood pressure in patients with type 2 diabetes on metformin with or without other antihyperglycaemic agents
    Hollander, P.
    Mathieu, C.
    Tong, C.
    Canovatchel, W.
    Meininger, G.
    DIABETOLOGIA, 2015, 58 : S352 - S352
  • [6] Practice pearl: the effect of canagliflozin on HbA1c and blood pressure in patients with type 2 diabetes mellitus
    Guthrie, Robert M.
    POSTGRADUATE MEDICINE, 2015, 127 (08) : 783 - 785
  • [7] Canagliflozin is superior to sitagliptin in reducing both HbA1c and body weight in patients with type 2 diabetes mellitus
    Schernthaner, G.
    Hieronymus, L.
    Jodon, H.
    Vijapurkar, U.
    Meininger, G.
    Canovatchel, W.
    DIABETOLOGIA, 2015, 58 : S351 - S352
  • [8] Canagliflozin reduces both HbA1c and body weight in patients with type 2 diabetes mellitus on background metformin
    Langslet, G.
    Davidson, J. A.
    Valentine, V.
    Vijapurkar, U.
    Canovatchel, W.
    Meininger, G.
    DIABETOLOGIA, 2014, 57 : S348 - S348
  • [9] The relationship of HbA1c and weight in the treatment of patients with type 2 diabetes
    Mathisen, AL
    Brockley, MR
    DIABETES, 2000, 49 : A117 - A117
  • [10] THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETES
    Ramos, M.
    Foos, V
    Ferrufino, C.
    Yu-Isenberg, K.
    Lamotte, M.
    VALUE IN HEALTH, 2018, 21 : S138 - S138
12345